KalshiVerificar disponibilidadeKYC obrigatório2% de taxaDados de resolução verificadosRazoavelmente calibradoProbabilidade implícita atual
Sim 98%
Qualidade do mercado
45 / 100
Baixa qualidadeVolume 24h
644,8 €
Liquidez
1,9 mil €
Baixa liquidezCompra / Venda
77.0% / 99.0%
Spread
22.0 pt
Spread amploDados do mercado
Atualizado há 2 minutos
17/06/26, 21:00 UTC1/01/27, 04:59 UTC
Tendências
Mercados Relacionados
Perguntas relacionadas para dar contexto, não uma comparação de contratos equivalentes.
FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026)
KalshiFDA decision: Venglustat by Sanofi (in 2026)
KalshiFDA decision: Ivonescimab by Summit Therapeutics (in 2026)
KalshiEbola pandemic in 2026?
PolymarketHantavirus pandemic in 2026?
PolymarketFDA approves skin cancer vaccine by which date?
PolymarketRegras
If the FDA's decision on Bepirovirsen by GlaxoSmithKline in 2026 is a full approval or an accelerated approval, the market resolves to Yes.
Liquida via:AppliedXL
- This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
- Bepirovirsen is an experimental antiviral medicine developed by GlaxoSmithKline that is designed to clear the hepatitis B virus from the body rather than just keeping it asleep.
- It belongs to a modern class of gene-silencing therapies that hunt down and destroy the virus's replication instructions.
- This is similar to intercepting and shredding a virus’s blueprints before its cell-invading factory has a chance to read them and build new viral copies.
Mercados abertos
Health & MedicinePOLYMARKETHantavirus pandemic in 2026?
- No-0.1pt97%
- Yes+0.1pt3%
- Volume total
- € 15,6 mi
- Volume 24h
- € 18,3 mil
KALSHIWill WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
- No96%
- Yes+1.9pt4%
- Volume total
- € 1,6 mi
- Volume 24h
- € 5,2 mil
KALSHIWhen will Intellia Therapeutics submit a BLA for Lonvo-z?
- before October+64.0pt98%
- before 2027+22.0pt98%
- before December+30.0pt98%
+3 mais resultados
POLYMARKETFDA approves skin cancer vaccine by which date?
- December 31,+6.0pt65%
- September+2.0pt41%
- June28%
- Volume total
POLYMARKETNew pandemic in 2026?
- No+0.5pt94%
- Yes-0.5pt6%
- Volume total
- € 916 mil
- Volume 24h
- € 1,5 mil
KALSHIMeasles cases in 2026?
- Above 300099%
- Above 400097%
- Above 6000-2.0pt57%
+2 mais resultados
- Volume total
- € 863,6 mil
- Volume 24h
- € 1 mil
- Ebola pandemic in 2026?
- Will 3 mg THC beverages be federally legal to sell?
- Ebola pandemic in 2026?
- Measles cases in U.S. in 2026?
- When will Heidi Overton be confirmed as Commissioner of the FDA?
- What will the average number of measles cases be during Trump's term?
- Will the FDA approve any psychedelic substance for medical use this year?
- When will the FDA reclassify BPC-157 to Category 1?
- FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
- Will the FDA approve CagriSema?
- When will Compass Pathways submit a NDA for COMP360 psilocybin?
Perguntas frequentes
- Quais são as probabilidades atuais de FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026)?
- A Kalshi cota Yes em 98% em 8 de setembro de 2026.
- Quando FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026) é resolvido?
- FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026) deverá ser resolvido em 1 de janeiro de 2027.
- Como FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026) é liquidado?
- A Kalshi liquida este mercado da seguinte forma: If the FDA's decision on Bepirovirsen by GlaxoSmithKline in 2026 is a full approval or an accelerated approval, the market resolves to Yes.